Advances in immunotherapy of M2 macrophages and gastrointestinal stromal tumor  

作　　者：Xiao-Ke Wang Xin Yang Tong-Han Yao Peng-Xian Tao Guan-Jun Jia De-Xian Sun Lin Yi Yuan-Hui Gu 

机构地区：[1]The First School of Clinical Medical,Gansu University of Chinese Medicine,Lanzhou 730000,Gansu Province,China [2]Department of General Surgery,Gansu Provincial Hospital,Lanzhou 730000,Gansu Province,China [3]School of Traditional Chinese and Western Medicine,Gansu University of Chinese Medicine,Lanzhou 730000,Gansu Province,China [4]Graduate School,Qinghai University,Xining 810016,Qinghai Province,China

出　　处：《World Journal of Gastrointestinal Oncology》2024年第7期2915-2924,共10页世界胃肠肿瘤学杂志(英文)

基　　金：Supported by the National Natural Science Foundation of China,No.82160842;Clinical Research Project of Research Fund of Gansu Provincial Hospital,No.23GSSYD-17.

摘　　要：Gastrointestinal stromal tumors(GIST)are the most common mesenchymalderived tumors of the GI tract.They can occur throughout the GI tract,and the survival time of some patients can be improved by first-line targeted therapy with imatinib.However,there are some limitations with imatinib treatment.Immunotherapy for GIST has attracted much attention in recent years,and as one of the most abundant cells in the GIST microenvironment,M2 macrophages play an important role in disease progression.They have unique anti-inflammatory and pro-tumorigenic effects and are one target for immunotherapy.This review summarizes the connection between different factors and the programmed death receptor-1/programmed death ligand-1 pathway and M2 macrophages to reactivate or enhance anti-tumor immunity and improve imatinib efficacy,and to provide new ideas for GIST immunotherapy.

关 键 词：Gastrointestinal stromal tumor M2 macrophage Inflammatory response Programmed death receptor-1 Programmed death ligand-1 IMATINIB IMMUNOTHERAPY Targeted therapy 

分 类 号：R735[医药卫生—肿瘤] R730.51[医药卫生—临床医学]